According to filings with the U.S. Securities and Exchange Commission, Delcath Systems is raising up to $7,001,113.00 in new funding. Sources indicate that as part of senior management Chief Executive Officer, Gerard Michel played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Delcath Systems
Delcath Systems, Inc. (NASDAQ- DCTH) is a specialty pharmaceutical and medical device company focused on the treatment of primary and metastatic liver cancers. Our proprietary product—Melphalan Hydrochloride for Injection for use with the Delcath Hepatic Delivery System (Melphalan/HDS)—is designed to administer high-dose chemotherapy to the liver while controlling systemic exposure. Delcath is in late-stage clinical development in the United States with initial commercial activities in Europe, where the Melphalan/HDS is marketed as a CE Marked device under the trade name Delcath Hepatic CHEMOSAT Delivery System for Melphalan (CHEMOSAT). Our commercial strategy for CHEMOSAT is to steadily grow clinical adoption in major European markets and utilize physician experience to support appeals for reimbursement. Since launch over 250 CHEMOSAT treatments have been performed at over 20 leading European cancer centers. In 2016, we launched our FOCUS Pivotal Study in Hepatic Dominant Ocular Melanoma, and are investigating orphan indications in hepatocellular carcinoma and intrahepatic cholangiocarcinoma. We believe Melphalan/HDS is uniquely positioned to treat the entire liver as a stand-alone or complementary therapy.

To learn more about Delcath Systems, visit http://delcath.com/

Contact:
Gerard Michel, Chief Executive Officer
518-743-8892

SOURCE: http://www.intelligence360.io
Copyright (c) 2024 SI360 Inc. All rights reserved.